Rockeby receives CE Mark approval for test 11:01, Thursday, 29...

Rockeby receives CE Mark approval for test
11:01, Thursday, 29 March 2007

Sydney - Thursday - March 29: (RWE Aust Business News) -
Singapore-based diagnostics group Rockeby biomed (ASX:RBY) has received
the European approval CE Mark for its Human Antigen Detection Test for
Influenza A.
With the obtaining of CE Mark notification, Rockeby will be able
to launch the product in both Europe and Australia, which generally has
a mutual reciprocal recognition of CE Mark as clearance for the import
of Medical Devices into Australia.
Clinical studies in Australia has proven that Rockeby's test is
able to detect various H5N1 strains of human origin, the cause of avian
influenza over 30 countries in the world, with numerous human
cases in Indonesia and Egypt.
The test can be used as a first line detection tool to determine
if the patients have been infected with the deadly bird flu virus.